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elderly. Of these patients, 31% received chemotherapy, 35.5% radiotherapy, and 10% 
both. The proportions of elderly patients receiving chemotherapy, radiation therapy, 
or both, remained stable throughout the study period. The most common indica-
tions for which elderly patients received chemotherapy included gastrointestinal 
(39%), lung (15%), breast (12%), and head and neck (9%) cancers. Overall, 17% of 
the elderly patients received > 2 lines of chemotherapy protocols; a similar rate 
(16%) was observed in the subgroup of patients ≥ 85 years of age. ConClusions: 
Approximately 30% of the cancer population treated in a large tertiary cancer center 
were elderly patients (≥ 75 years of age). The findings of this study may promote a 
discussion regarding medical resources, staff training, and planning a designated 
evaluation for geriatric cancer patients that should include special consideration 
to the patients’ comprehensive functioning.
PCN279
SyStemiC treatmeNt of metaChroNouS metaStaSeS after Curative 
treatmeNt of BreaSt CaNCer
Kuiper J.G.1, van Herk-Sukel M.P.P.1, van Gestel Y.R.B.M.2, Voogd A.C.2, Lemmens V.E.P.P.2, 
Siesling S.3
1PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 2Comprehensive 
Cancer Centre the Netherlands (IKNL), Eindhoven, The Netherlands, 3Comprehensive Cancer 
Centre the Netherlands (IKNL), Utrecht, The Netherlands
objeCtives: To describe systemic treatment of metachronous metastases and 
the reasons of not receiving systemic treatment in patients with breast cancer.  
Methods: Patients diagnosed with breast cancer without metastasis at initial diag-
nosis (M0) between 2006-2008 were selected from the Eindhoven Cancer Registry. 
By means of active follow-up by the Cancer Registry staff until January 2012, data 
on development of metastatic disease, treatment, and reasons of not receiving sys-
temic treatment were collected directly from the patient files. Results: Of 1,382 
patients diagnosed with M0 breast cancer, 116 (8%) developed metachronous metas-
tases during a median follow-up of 4.4 years. Of the patients developing metachro-
nous metastases, 86 (74%) patients received systemic treatment with a median (± 
SD) age of 59.7 (± 13.4) years. Of these, 46 patients (53%) received chemotherapy, 19 
patients (22%) received hormonal therapy and 21 patients (24%) received a combi-
nation of chemotherapy and hormonal therapy. Median (± SD) age of the patients 
who did not receive systemic treatment (n= 30) was 70.0 (± 15.9) years. Of the 67 
patients receiving chemotherapy, 17 patients (25%) were treated with taxane con-
taining chemotherapy as first-line treatment. Of the 30 patients without any sys-
temic treatment, 10 patients received radiotherapy, 3 patients underwent surgery 
and 6 patients refrained from systemic treatment. Other reasons for not receiving 
systemic treatment were: extensiveness of metastases/life expectancy (n= 4), death 
before first application of chemotherapy (n= 4), high age (n= 1), comorbidities (n= 1) or 
bad experience with chemotherapy in the past (n= 1). ConClusions: Of the initially 
M0 breast cancer patients who developed metastases during follow-up the majority 
received systemic treatment. A quarter of the patients did not receive systemic treat-
ment, primarily due to other treatment policies, refraining from treatment or poor 
condition. This study provides more insight into the treatment of metachronous 
metastases in the Netherlands.
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objeCtives: To describe current guidance on BRCA testing practices in patients 
with ovarian cancer (OC) in China, European countries, and US. Methods: 
Guideline databases like National Guideline Clearinghouse, Guidelines 
International Network, and National Institute for Health and Care Excellence 
were searched for guidelines in both ovarian and breast cancer. Additionally, 
relevant medical societies like United States Preventive Services Task Force, 
National Society of Genetic Counselors, American Society of Clinical Oncology, 
European Society for Medical Oncology, European Society of Human Genetics, 
Chinese Society of Clinical Oncology, Chinese Academy of Medical Sciences, and 
International Cancer Genome Consortium were considered. Guidelines were 
included if they contained recommendations for BRCA testing in OC or patient 
characteristics for BRCA mutation in OC, were published after 2003, were cur-
rently valid, and published in English, Chinese or German language. Results: The 
search revealed a total of 22 guidelines. Ten breast cancer guidelines were excluded 
because they did not add any information beyond that found in guidelines for OC. 
Ten out of 12 guidelines recommend genetic testing for healthy individuals with 
familial history of ovarian or breast cancer and a personal history of breast cancer. 
Most guidelines differ in their description of selection criteria such as degree of 
relationship between affected individuals and counselee, age at diagnosis, and 
individual history of early onset cancer. Five out of 12 guidelines also recommend 
screening for patients of Jewish Ashkenazi or Icelandic descent. ConClusions: 
Current guidance recommends genetic testing primarily for healthy individuals; 
a few guidelines recommend testing in diagnosed ovarian cancer patients. Using 
current recommendations a substantial number of patients with OC due to an 
inherited BRCA mutation are missed. With options for treatment aimed at muta-
tion carriers, identification of all OC patients with BRCA mutation will facilitate a 
personalized therapy and identify family members at risk of cancer.
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tive and level of analysis (macro or meso level), and whether regression correction 
should be performed. A limitation of the illustrative case study was that costs of 
sustainability activities were not collected.
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objeCtives: To critically assess cost-sharing schemes between payers and market-
ing authorization holders (MAHs) that are in some jurisdictions used as a means to 
control public spending on prescription drugs. Methods: Cost-sharing scheme can 
be theoretically expressed as the two-step process, where the discount of the MAH 
equals p when x≤ n, and 0 when x> n, where n is the number of weeks/months with 
reduced price of a drug and x is the length of treatment in weeks/months. Within 
such a scheme, the overall discount has no lower limit as it is inversely proportional 
to x, i.e., np/x. Payers and MAHs may estimate and agree upon the expected length 
of treatment x= m0 based on, e.g., randomized clinical trials (RCTs); however, these 
estimates may be unreliable due to, inter alia, market power of MAHs that could 
influence prescribers to select those patients that will remain longer on the treat-
ment. Results: Two-step cost-sharing scheme results in the effective discount that 
is lower than expected discount by (x-m0) /x, once x surpasses m0. The lower limit 
of the discount can be achieved if the two-step cost-sharing scheme is modified 
by an additional step: the discount then equals (i) p when x≤ n, (ii) 0 when m0≥ x> n, 
and (iii) np/m0 when x> m0. Cost-sharing scheme in this format guarantees that the 
effective discount remains at the expected level of np/m0 and gives no incentive 
to MAHs to exert their market power and prolong treatment duration. We applied 
our simple model to a real-life case of innovative oncological drug (p= 100%; n= 6 
weeks; m0= 30 weeks). ConClusions: We have shown that cost-sharing schemes 
should incorporate an additional step in order to ensure the effective control of 
expenditure for drugs. This finding may be of value to those jurisdictions that resort 
to cost-sharing as a tool in curtailing prescription drug costs.
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objeCtives: Limited data regarding effectiveness, efficacy, safety or cost-effective-
ness at marketing authorization reflect uncertainties that payers try to counteract 
with performance-based risk-sharing arrangements (PBRSAs). PBRSAs link medi-
cines’ reimbursement to health outcomes and seem to reduce these uncertainties 
– especially for stratified medicine in oncology. We wanted to identify PBRSAs for 
stratified medicine in oncology to discuss advantages, disadvantages, their cost-
effectiveness and whether they could reduce uncertainties. Methods: A litera-
ture search was conducted in bibliographical databases from 2003-2013. Searching 
websites of reimbursement bodies from Australia, Canada, Germany, UK, USA and 
hand searching completed the search strategy. Publications were eligible if reim-
bursement for stratified medicine in oncology was linked to health outcomes. 
A self-developed checklist based on ISPOR Task Force Report on PBRSAs (Garrison 
et al., [Value Health. 2013; 16 (5): 703-19]) was used to conduct quality assessment. 
This checklist consists of five domains assessing the quality of a PBRSA: descrip-
tion, desirability and rationale, implementation, evidence collection and evalua-
tion. Results: We identified 43 publications resulting in 40 PBRSAs (Canada: 12, 
Italy: 9, UK: 7, Australia: 8, The Netherlands: 2, USA: 1, Slovenia: 1). Most schemes are 
related to leukemia (mainly dasatinib, imatinib and nilotinib). These PBRSAs were 
categorized in subcategories: risk sharing schemes (RSS) such as ‘outcomes guar-
antees’ (n= 7), ‘conditional treatment continuation’ schemes (n= 22), ‘money back 
guarantees’ (n= 3) and coverage with evidence development schemes (CED) such as 
‘only in research’ schemes (n= 8). Quality assessment was limited by lack of reporting 
on PBRSAs’ details. Therefore, ambiguity remains about PBRSAs’ cost-effectiveness 
and their reduction of uncertainties. ConClusions: RSS provide faster access to 
therapies, guarantee reimbursement for manufacturers and possibly cost contain-
ment for payers, but do not necessarily collect additional evidence. The administrative 
burden and related costs appear to be huge. Existing value of information analysis 
approaches were not applied to CED schemes. Evaluations of PBRSAs are necessary 
to assess their value.
PCN278
aNti-CaNCer treatmeNtS iN elderly (≥ 75 yearS old) PatieNtS:  
a retroSPeCtive aNalySiS
Gordon N., Stemmer S.M.
Davidoff Center, Rabin Medical Center, Petach-Tikva, Israel
objeCtives: Primary: To describe the use of anti-cancer treatments in elderly 
patients (≥ 75 years of age) at the Davidoff Center between 2006 and 2013. Secondary: 
To investigate the correlations between anti-cancer treatments and socio-demo-
graphic- and cancer-related parameters. Methods: The analysis included all 
elderly (≥ 75 years) cancer patients treated at the Institute of Oncology, Davidoff 
Center between 2006 and 2013. The analysis included Israeli residents (i.e., “medical 
tourists” were excluded). Patients who were treated elsewhere and had a single con-
sultation appointment at the Davidoff Center were also excluded from the analysis. 
The following parameters were assessed: demographic variables, cancer diagnosis, 
chemotherapy and radiation treatments received, clinic visits, hospitalizations, and 
the utilization of other health-related services. Results: Out of 21,009 new patients 
treated at the Davidoff Center between 2006 and 2013, 6, 553 patients (31%) were 
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treatment effects using multivariate meta-analyses. Results: Given the variation 
in analysis populations and timing of outcome assessment across RCTs, a limited 
number of studies were considered sufficiently similar for meta-analyses. For NP, 
a positive relationship between microbiological eradication and cure (correlation 
coefficient of 0.84; 95%CI 0.07, 0.98; 5 studies) and a negative relationship between 
eradication and mortality (-0.86; 95%CI -0.97, -0.34; 7 studies) were observed. For 
cIAI, clinical outcome was used as a proxy measure for microbiological eradication, 
but no correlation with mortality was identified. No relationship was observed for 
cUTI either. ConClusions: Relationships between treatment effects in terms of 
eradication and clinical cure and between eradication and mortality were identified 
for NP. For cIAI and cUTI, the relationship between microbiologic eradication and 
treatment effects is unclear based on available study level RCT evidence. Given the 
great variation between studies and several uncertain findings, evaluations using 
patient level data are recommended.
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objeCtives: Human Immunodeficiency Virus (HIV) has become a chronic man-
ageable disease after the advent of combination antiretroviral therapy (ART). Since 
launching of ART, the numbers of patients enrolled in to ART are increasing in 
developing countries like India. In this study we aim to analyze clinical and immu-
nological outcomes of ART in a community care hospital. Methods: A retrospec-
tive cohort study was conducted by including 800 ART naive HIV infected adult 
patients initiated on ART. All patients survived in ART centre at Mysore, India for 12 
months from January 2013 to January 2014 were included. Parameters like weight, 
hemoglobin, WHO clinical stage and CD4 count were collected from medical records 
before initiation and after completion of 12 months ART. Outcomes of ART were 
analyzed by paired T- test using SPSS version 21. Results: A statistically signifi-
cant improvement was observed for weight [53.9 (11.9) to 58.2 (32.6) kg; P = 0.002] 
and CD4 count [206.6 (177.4) to 331.1 (220.5); P = 0.001] at the end of 12 months of 
ART treatment. Whereas, marginal improvement in hemoglobin [11.94 (4.3) to 11.98 
(5.7) g%; P = 0.91] was observed, though it was not statistically significant. Also 
observed a significant increase in percentage of patients in WHO clinical stage I 
(64-82%) and decrease in number of patients in stages II (13-14%), III (5-2%) and IV 
(18-12%). ConClusions: The improvement in weight and CD4 count are indirect 
parameters of > 95% medication adherence and of sustained viral suppression. The 
optimal outcome would have been all patients in WHO clinical stage I or II and none 
in III and IV, but in this study 2% and 12% of patients continued to be in stage III and 
IV respectively. This may be due to development of opportunistic infections such as 
tuberculosis which is endemic in India.
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objeCtives: Oritavancin (ORI) is a lipoglycopeptide with bactericidal activity 
against Gram-positive bacteria including MRSA. This analysis evaluated efficacy 
and hospital length of stay of ORI for patients with acute bacterial skin and skin 
structure infections (ABSSSI) who received care in the SOLO program in the US 
and Eastern Europe. Methods: SOLO I and II were identically-designed compara-
tive, multicenter, double-blind, randomized studies to evaluate the efficacy and 
health care resource utilization (HRU) of single 1200 mg dose IV ORI versus 7-10 
days of twice-daily intravenous (IV) vancomycin (VAN) for the treatment of ABSSSI. 
SOLO protocols were amended (Amendment 2) to allow outpatient treatment at the 
investigator’s discretion. Efficacy and HRU of treatment were assessed in inpatient 
and outpatient settings. Efficacy for the European Medicines Agency (EMA) was 
investigator-assessed clinical cure 7-14 days after end of treatment. HRU endpoints 
were hospitalization rate and length of stay (LOS) in days if the patient was hos-
pitalized. Results: In the combined studies, 1959 patients were in the modified 
intent-to-treat (mITT) population; 1,172 patients (60%) received a portion of their 
care in as inpatients; 202 patients were treated in Eastern European countries (EUC: 
Russian Federation, Romania and Ukraine) and 1,165 were treated in the US. Clinical 
cure rates were similar for ORI and VAN in both regions (86.1% and 84.2% in EUC, 
80.6% and 77.9% in the US. The average LOS (ALOS) in the EUC was longer than in 
the US (14.9 and 14.7 vs. 6.0 and 6.4 days). ConClusions: Clinical cure rates at PTE 
were similar between ABSSSI patients who received a single dose of ORI or 7-10 days 
of VAN in SOLO, but the ALOS in the US was considerably shorter than in Eastern 
Europe. Using oral or long-acting antibiotic treatments may reduce the numbers of 
inpatient IV antibiotic administrations, which has been associated with reduced 
LOS in other studies.
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objeCtives: Vaccination has proven to be an efficient preventive strategy against 
influenza infection. Each year, two genetically distinct influenza B lineages co-
circulate. Current trivalent influenza vaccines (TIVs) contain only one influenza 
B and two influenza A strains, but vaccine mismatch are frequent due to the 
difficulty to predict which B lineage will predominate during the next epidemic. 
objeCtives: Inadequate control over emesis during cancer chemotherapy can 
adversely affect patient’s quality of life, delay the subsequent chemotherapy cycle 
and may lead to poor adherence to treatment. This study was conducted to assess 
appropriateness of anti-emetics use in the management of chemotherapy induced 
nausea and vomiting. Methods: A prospective observational study was conducted 
for a period of 6 months at private cancer hospital. Medical records of the patients 
on chemotherapy were reviewed and patients were interviewed to assess the pre-
scribing pattern of anti-emetics and its appropriateness. Chemotherapy regimen 
and given anti-emetics for each patient were recorded and reviewed with respect 
to National Comprehensive Cancer Network (NCCN) guidelines for anti-emesis to 
ensure the appropriateness of drug use. Results: Of 346 patients’ record reviewed, 
majority (74%) of them were prescribed with drugs which are highly emetogenic 
followed by 17% of them with moderately emetogenic and 9% of them with low 
emetogenic potential. Unlike 30% of patients who were added with NK-1 recep-
tor antagonist (NK1RA) either in oral or intravenous formulation, majority (n= 184, 
70.76%) of the patients receiving highly emetogenic regimen were placed on com-
bination of 5-HT3 antagonist and corticosteroids without adding NK1RA for pre-
vention of acute and delayed emesis. Majority patients (64%) receiving moderately 
emetogenic regimen were prescribed with combination of 5-HT3 antagonist and 
corticosteroids and remaining received combination of metoclopramide with cor-
ticosteroids. Most of the patients (82%) receiving low emetogenic regimen were 
prescribed with combination of metoclopramide and corticosteroids and remain-
ing were prescribed with 5-HT3 antagonist and corticosteroid. Over all, selection of 
anti-emetic regimen was inappropriate for 32% (n= 112) patients. Dosage, frequency 
and duration of anti-emetic use were inappropriate in 18%, 38% and 8% respec-
tively. ConClusions: Most of the patients received same anti-emetic regimen for 
highly emetogenic and moderately emetogenic agents. Cost was the limiting factor 
to choose an appropriate anti-emetic regimen.
iNfeCtioN – Clinical outcomes Studies
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objeCtives: Cobicistat, a CYP3A inhibitor, is a novel, alternative pharmacoen-
hancer to ritonavir. A fixed-dose combination once-daily formulation that contains 
darunavir and cobicistat has been developed to simplify dosing and to enhance 
patient convenience. This analysis compared the virological response of a cobi-
cistat-boosted versus a ritonavir-boosted darunavir QD regimen by testing for non-
inferiority. Methods: Patient level data on 800mg QD darunavir treatment from 3 
phase 3 trials (GS-216-0130, TMC114-C211, TMC114-C229) were combined for analy-
sis of virological response at Week 48, using the Snapshot algorithm methodology. 
Patients were HIV-1-infected treatment-naïve or -experienced with no darunavir 
resistance-associated mutations at baseline. The non-inferiority margin was set 
at 0.531 on the odds-ratio (OR) scale, which corresponded to a 12% non-inferiority 
margin on the risk-difference scale, assuming an 80% response rate.  Multiple logis-
tic regression was used to adjust for differences in baseline patient characteristics 
(age, gender, race, baseline CD4+ T-cell counts, baseline HIV-1 RNA, HIV disease 
status, and previous antiretroviral use) and level of darunavir treatment adher-
ence. A sensitivity analysis was performed on data from patients with viral load<50 
copies/mL according to time to loss-of-virological response (TLOVR) algorithm at 
week 48. Results: Treatment with darunavir/cobicistat(800/150mg QD, n=313) was 
non-inferior to darunavir/ritonavir (800/100mg QD, n=637). Unadjusted virological 
response rates were 81% and 78%, respectively. The adjusted odds ratio [95% CI] 
for virological response comparing darunavir/cobicistat with darunavir/ritonavir at 
week 48 was 0.878 [0.576, 1.339] (Snapshot). The 95% CI lower boundary was above 
the defined non-inferiority margin. The sensitivity analysis gave similar results: 
TLOVR OR=0.803 [0.534, 1.208]. ConClusions: This adjusted analysis of pooled 
phase 3 data of an 800mg once-daily darunavir dose showed that darunavir/cobi-
cistat has non-inferior efficacy compared with darunavir/ritonavir.
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objeCtives: Infections caused by Gram-negative bacteria, including nosocomial 
pneumonia (NP), complicated urinary tract infections (cUTI), and complicated 
intra-abdominal infections (cIAI), have been increasing. Although microbiological 
eradication is on the presumed causal path from antibiotic susceptibility to clini-
cal success, other factors impact clinical success rates as well. This study assessed 
the relationship between microbiological eradication and clinical outcomes for NP, 
cUTI, and cIAI based on randomized controlled trial (RCT) evidence. Methods: 
A systematic literature search identified RCTs (25 NP trials, 10 cUTI, 28 cIAI, and 1 
cUTI & cIAI trial) that met the following criteria: Adult patients with cUTI, cIAI, or 
NP; Gram-negative bacteria present in at least a fraction of the population; treat-
ment including coverage of Gram-negative bacteria; any measure of microbiological 
eradication and either clinical response, cure or mortality. RCTs with information on 
both eradication and clinical outcome were selected to estimate their relationship to 
